Submission of Outcome of board meeting held on 12th August, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories' board approved Q1 FY26 results showing strong growth: revenue from operations nearly doubled to Rs. 25.33 crore (from Rs. 13.15 crore YoY), while profit after tax rose about 24% to Rs. 2.09 crore. The board allotted 9.39 lakh equity shares at Rs. 40 each (Rs. 10 face value + Rs. 30 premium) upon warrant conversion to 11 non-promoter strategic investors, bringing in Rs. 2.82 crore and lifting paid-up equity capital from Rs. 9.83 crore to Rs. 10.77 crore. The 32nd Annual General Meeting is scheduled for Friday, 12 September 2025 via video conferencing, with book closure from 6–12 September. The board also authorized the Whole Time Director to discuss a potential acquisition of Sriven Pharmachem India Private Limited, and recommended special resolutions to raise borrowing, investment, and guarantee limits up to Rs. 500 crore each, subject to shareholder approval.
Strong YoY revenue and profit growth is a positive signal for the business, but the share allotment expands the equity base by roughly 9.6%, which will dilute existing shareholders slightly. The proposed Rs. 500 crore borrowing/limit hikes and the Sriven Pharmachem acquisition exploration are the key catalysts to watch at the upcoming AGM on 12 September.